This Week in Biotech – DailyFinance

by admin on May 25, 2013

This Week in Biotech
DailyFinance
XenoPort's management noted that the company plans to cease development of AP and instead focus on the commercial development of recently approved restless leg syndrome drug Horizant, and its remaining clinical pipeline. The ugly. Finally, in a case of

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: